Premium
P2‐301: DIFFERENCES IN COGNITIVE PROFILE BETWEEN BIOMARKER CONFIRMED ALZHEIMER'S DISEASE AND VASCULAR DEMENTIA
Author(s) -
Koh Chen Ling
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.06.2708
Subject(s) - dementia , biomarker , episodic memory , vascular dementia , cognition , disease , cognitive decline , alzheimer's disease , memory clinic , medicine , psychology , effects of sleep deprivation on cognitive performance , oncology , psychiatry , biology , biochemistry
Background: Although the differences in the cognitive profile between AD and Vascular Dementia (VaD) have been extensively studied, there is likely to have been overlap between the 2 groups as AD and VaD were defined using only clinical criteria. Comparison of the cognitive profile of AD and VaD using biomarker supported diagnosis is needed. Methods: 68 participants (Mage1⁄458.1, Meducation1⁄4 11.7 years, 32 males) were recruited from a tertiary dementia centre. Participants underwent cerebrospinal fluid (CSF) testing for AD biomarkers. Participants with established AD range b-amyloid were classified as Pure AD group while patients with Staal’s Cerebrovascular Disease score of at least 1 and b-amyloid not in the AD range were classified as Pure VaD. Healthy Controls did not have AD range b-amyloid and had a zero Staals score. All participants underwent evaluation for global cognition, executive function, attention/working memory, language, episodic memory and visuospatial domains. Regression analysis was used to test the associations between cognitive domains and diagnostic groups. Results: Participants with AD and VaD were comparable on demographic and vascular risk factors. Global cognition (MMSE) was not significantly different between AD and VaD. Episodic Memory and Attention/Working memory was significantly worse in Pure AD. Executive function was not significantly different between the 2 groups. Conclusions: Using biomarker confirmed diagnosis for AD and VaD, the clinical believe that patients with VaD have worse executive function and attention span compared to AD was not demonstrated. Neurocognitive measures alone are insufficient to differentiate AD from VaD. nday, July 15, 2019